A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Advanced Triple Negative Breast Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2019
Price : $35 *
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 24 Apr 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Feb 2019 Planned initiation date changed from 30 Jan 2019 to 1 Apr 2019.
- 15 Nov 2018 Planned initiation date changed from 30 Oct 2018 to 30 Jan 2019.